JMP Securities Reiterates Market Outperform on Rallybio, Maintains $16 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Jonathan Wolleben has reiterated his 'Market Outperform' rating on Rallybio (NASDAQ:RLYB) and maintained a price target of $16.
July 25, 2023 | 11:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has reiterated its 'Market Outperform' rating on Rallybio, maintaining a price target of $16.
The reiteration of the 'Market Outperform' rating by JMP Securities indicates a positive outlook for Rallybio. The maintained price target of $16 suggests that the analyst believes the stock is undervalued at current levels. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100